JANUARY 20, 2010

Blasts From The Past
To view past issues,
click on the Techno-Dude


Click Here

We'll be there -- come join us!
FlexAct: Integrated, systematic single-use solutions
Trends and Developments In BioProcess Technology
Career Development
We post announcements for the most valuable training courses, networking opportunities, and job openings. Send us yours.
Training in Aseptic
Processing Techniques
and Basic Microbiology
Cell Culture Engineering XII
- April 25-30, 2010 -
Parallel Forums: North American Vaccine/Cell & Gene Therapy
- January 25-27, 2010 -
Masthead Image

Provided by BioLife Solutions, Inc., Bothell, Washington. (Also featured in the May/June 2004 issue of the BioProcessing Journal.)

Description: Coronary artery endothelial cells following one day at 4°C in HTS-FRS, stained with Mitro Tracker and AlexaFluor 488 (actin).

Email the techie your image for an upcoming Techno-Blast.

Advertising Info
Please contact the closer to obtain a quote for advertising, or to learn how you can become a sponsor. To view ad sizing specifications, click here.
Suggested Reading
A Summary of the Manufacture, Biochemical Characterization, and Virological Safety Demonstration of the Mouse mAb CB.Hep-1 Used to Produce the Hepatitis B Vaccine
Viral Reference Material Update

Seqwright has donated their time and materials to help characterize the new AAV2 reference material. The company will sequence the Adeno-Associated Virus, serotype 2 (AAV-2) vector and the associated plasmid. Seqwright also donated their services to sequence the adenoviral reference material Ad5.

Florida Biologix is donating its services to perform long-term stability testing on the Adenoviral, serotype 5 Reference Material which has been in use since 2002. After over seven years in storage at ATCC, the vector remains stabile as measured with total virus particles and infectious titer assays.

Both reference materials are intended for use in validating internal reference standards and assays. They were produced under the guidance of formal working groups which included non-voting FDA members. The production process and all testing have been well documented on the BioProcessing Journal website. For even more information and to purchase these materials, please visit the ATCC website.

Sponsored Link

We are proud to support BioPlan Associates, Inc. as they collect data for their
7th Annual Report and Survey of Biopharmaceutical Manufacturing. This global benchmarking study provides the latest trends and advancements in biomanufacturing that we all need for strategic planning. Key topics include capacity optimization, lost batches, outsourcing, disposables usage, expression enhancement, workforce development, and strategic alliances.

Please join me by sharing your opinions and perspectives in the online survey (click here). As a participant in this important international study, you will be provided with a free summary of the results.

Keith L. Carson

A Message From "The Boss"

Our best wishes to you for a prosperous 2010. And here’s my prescription for better financial times:

First, we need banks to return to either commercial or investment banking, since mixing the two has been a disaster for everyone except bank executives.  We need commercial banks to concentrate on their communities and make the loans that will help small businesses take risks, and especially retain, hire, and train the people they will need as the economy improves.  Interest rates are incredibly low, and it’s my guess that there will be even more government absorption of risk through the Small Business Administration, and other programs. 

But of course, we need the government to be fairly consistent in how it stimulates and regulates our banks.  It can’t expect ever higher capital levels and lower risk taking while demanding that the banks make more loans.  A balance for these expectations must be established quickly.

And then we have the investment banks, which all but stopped initial public offerings (IPOs) to gamble on exotic instruments and the latest bubbles.  Without IPOs, the only real way for investors and founders to cash out was to sell the company.  And the past decade has proven to me that mergers and acquisitions (M&A) have done little more than pay big returns to top company management and law firms.  Everyone else has come up short.

The commercial and investment banking functions have become far too entangled, and the result has been the mass disenfranchisement of small business borrowers and investors alike.  And to make things worse, we let the banks get into insurance where they became even more distracted by insuring crazy investments they never should have created. 

So I suggest we all keep pushing for government-backed loan programs like SBA, which helped develop the small-business-based economies that created so much innovation and so many jobs, and support regulation that restores investment banking functions which will give investors more options.

The Journal

There's still time to advertise
your products and services
in the Spring 2010 issue.
Contact BPJ Now!

The Fall 2009 issue is
now available on your
Amazon Kindle.
Check it out!

Sponsored Link
Pulling MAb charge variants and derivatives apart is one of the top challenges many analytical scientists face today.

Click here to see the eight individual peaks separated on non-porous 10µm 4.6x250mm column, and imagine what you can achieve with Antibodix NP5, NP3, or NP1.7.

The Sepax team challenges you to test it out yourself to see the difference.
Getting It Right
Five pharmaceutical manufacturing facilities were selected as category winners in the 6th annual "Facility of the Year Awards (FOYA)" program sponsored by ISPE, INTERPHEX, and Pharmaceutical Processing magazine.

The winners: Biogen Idec - Genentech - MannKind Corp. -
Pfizer Biotech Ireland - Pfizer Ireland Pharmaceuticals
Click for details.
Techno-Blast Content

We feature articles, presentations, assays, techniques, protocols, blog chats, reviewer comments, product tutorials, virtual tours, application data, and pretty much any other form of online material that's needed to develop and produce safe and effective products.

Technologies include essentially all the unit operations and support functions involved in bioprocessing, such as cell engineering and banking, cell culture scale-up, filtration, purification, media development, assay development, regulatory affairs, and facility design.

We hope you enjoy visiting our site and find the content both valuable and timely. Forward your comments to the boss.


We cover the toughest applications which tend to receive very little coverage elsewhere:

» Viral Vectors
» Cellular Vaccines
» Vaccines
» Antibodies
» Recombinant Proteins
» Tissue Regeneration
» Cell Engineering
» Cell Banking
» Facilities
» Quality Systems
» Safety and Efficacy

Submission Formats
Feel free to submit streaming video, YouTube postings, PowerPoint presentations, and of course, PDF, HTML, Word, and Excel documents. Once we receive them, you will be contacted to discuss the optimal method(s) for Techno-Blast incorporation.
If you would like to help review submissions for a specific application or technology area, please contact the boss. Include your full contact information, the area(s) in which you would like to contribute, and any relevant experience you’ve had on a review or advisory board.
© 2010 BioProcess Technology Network Ltd
PO Box 3975, Norfolk, VA 23514 USA » Phone: 757.502.7422, Fax: 757.257.3800
Home Page: www.biotechnoblog.net » Email: the-gofer@biotechnoblog.net